NASDAQ: ACRVAcrivon Therapeutics Inc Stock
$9.39-1.15 (-10.91%)
Updated Apr 19, 2024
ACRV Price
$9.39
Fair Value Price
$1.42
Market Cap
$212.56M
52 Week Low
$3.19
52 Week High
$14.30
P/E
-3.43x
P/B
1.75x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$60.39M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.14
Operating Cash Flow
-$43M
Beta
0.96
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ACRV Overview
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ACRV scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ACRV ($9.39) is overvalued by 560.85% relative to our estimate of its Fair Value price of $1.42 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ACRV ($9.39) is not significantly undervalued (560.85%) relative to our estimate of its Fair Value price of $1.42 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ACRV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ACRV due diligence checks available for Premium users.
Be the first to know about important ACRV news, forecast changes, insider trades & much more!
ACRV News
Valuation
ACRV fair value
Fair Value of ACRV stock based on Discounted Cash Flow (DCF)
Price
$9.39
Fair Value
$1.42
Overvalued by
560.85%
ACRV ($9.39) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ACRV ($9.39) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ACRV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ACRV price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.43x
Industry
15.81x
Market
40.51x
ACRV price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.75x
Industry
5.74x
ACRV is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ACRV's financial health
Profit margin
Revenue
$0.0
Net Income
-$19.3M
Profit Margin
0%
ACRV's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$138.3M
Liabilities
$17.1M
Debt to equity
0.14
ACRV's short-term assets ($129.69M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ACRV's short-term assets ($129.69M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ACRV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$12.4M
Investing
$20.5M
Financing
-$2.0M
ACRV's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ACRV vs Biotech Stocks
Acrivon Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.